Methods for the design of vasomotor symptom trials: the menopausal strategies: finding lasting answers to symptoms and health network

Menopause. 2014 Jan;21(1):45-58. doi: 10.1097/GME.0b013e31829337a4.

Abstract

Objective: This report describes the Menopausal Strategies: Finding Lasting Answers to Symptoms and Health network and methodological issues addressed in designing and implementing vasomotor symptom trials.

Methods: Established in response to a National Institutes of Health request for applications, the network was charged with conducting rapid throughput randomized trials of novel and understudied available interventions postulated to alleviate vasomotor and other menopausal symptoms. Included are descriptions of and rationale for criteria used for interventions and study selection, common eligibility and exclusion criteria, common primary and secondary outcome measures, consideration of placebo response, establishment of a biorepository, trial duration, screening and recruitment, statistical methods, and quality control. All trial designs are presented, including the following: (1) a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effectiveness of the selective serotonin reuptake inhibitor escitalopram in reducing vasomotor symptom frequency and severity; (2) a two-by-three factorial design trial to test three different interventions (yoga, exercise, and ω-3 supplementation) for the improvement of vasomotor symptom frequency and bother; and (3) a three-arm comparative efficacy trial of the serotonin-norepinephrine reuptake inhibitor venlafaxine and low-dose oral estradiol versus placebo for reducing vasomotor symptom frequency. The network's structure and governance are also discussed.

Conclusions: The methods used in and the lessons learned from the Menopausal Strategies: Finding Lasting Answers to Symptoms and Health trials are shared to encourage and support the conduct of similar trials and to encourage collaborations with other researchers.

Trial registration: ClinicalTrials.gov NCT00894543 NCT01178892 NCT01418209.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Biomedical Research / organization & administration*
  • Citalopram / therapeutic use
  • Cyclohexanols / therapeutic use
  • Dietary Supplements
  • Double-Blind Method
  • Estradiol / therapeutic use
  • Estrogens / therapeutic use
  • Exercise Therapy
  • Fatty Acids, Omega-3 / therapeutic use
  • Female
  • Hot Flashes / therapy
  • Humans
  • Menopause / physiology*
  • Outcome Assessment, Health Care
  • Patient Selection
  • Placebos
  • Quality Control
  • Randomized Controlled Trials as Topic / methods*
  • Research Design*
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Statistics as Topic
  • Sweating
  • Time Factors
  • Venlafaxine Hydrochloride
  • Yoga

Substances

  • Cyclohexanols
  • Estrogens
  • Fatty Acids, Omega-3
  • Placebos
  • Serotonin Uptake Inhibitors
  • Citalopram
  • Estradiol
  • Venlafaxine Hydrochloride

Associated data

  • ClinicalTrials.gov/NCT00894543
  • ClinicalTrials.gov/NCT01178892
  • ClinicalTrials.gov/NCT01418209